Sponsor: Novocure
Sponsor Study ID: TRIDENT/ EF-32
Study Title: EF 32 (TRIDENT): A Pivotal Randomized, Open Label Study of Optune® (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
CTO #: 103299
NCT Number: NCT04471844
Phase: N/A
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Brain and Nervous System
Study Objectives: To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.